Boston, MA — November 17–19, 2025 — MatrileX Laboratories participated in the 9th Antifibrotic Drug Development Summit, a leading industry forum bringing together experts across fibrosis biology, translational research, and early clinical development.
Co-Chair of Workshop A
Professor Richard E. Gilbert co-chaired Workshop A, “Engineering Preclinical Models that Better Recapitulate the Chronic & Progressive Nature of Human Fibrosis,” guiding discussions on improving preclinical model fidelity, adopting chronic and functionally relevant study designs, and aligning animal outcomes with human disease biology.
Contributor to a High-Impact Clinical-to-Preclinical Translation Panel
Professor Gilbert also contributed to the panel, “How Early Clinical Learnings Can Inform Smarter Preclinical Strategy,” addressing how Phase 2 signals, patient heterogeneity, and biomarker responses should shape next-generation preclinical studies and translational decision-making.
MatrileX is proud to contribute to scientific leadership within the antifibrotic research community and remains committed to advancing clinically aligned preclinical models that improve translational success.